Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
219 stopped studies mapped to Female Reproductive System Carcinoma and descendants · 90% state a reason
Over the 219 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02834975 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial… | Phase 2 | terminated | Jul 15, 2016 | University of Miami | Investigator left institution | Investigator |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients… | Phase 3 | withdrawn | Feb 6, 2023 | EQRx International, Inc. | The study is being closed based on corporate changes at EQRx and is not related to any efficacy or… | Safety / toxicity |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous… | Phase 3 | terminated | May 9, 2013 | Pfizer | Per recommendation of the DMC, enrollment into the study was discontinued in April 2016 after the… | Efficacy / futility |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With…(AXLerate-OC) | Phase 3 | terminated | Jan 28, 2021 | Aravive, Inc. | There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel… | Safety / toxicity |
| NCT01041027 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk… | Phase 2 | terminated | Dec 30, 2009 | Albert Einstein College of Medicine | Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid. | Enrollment / accrual |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | Phase 3 | terminated | Apr 15, 2022 | Mersana Therapeutics | Study Terminated by Sponsor | Other (stated, no rule matched) |
| NCT04907968 | Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With…(UPGRADE) | Phase 1 | terminated | Jun 1, 2021 | Mersana Therapeutics | Study Terminated by Sponsor | Other (stated, no rule matched) |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and… | Phase 2 | withdrawn | Mar 25, 2022 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating… | Phase 2 | terminated | Apr 14, 2014 | Albert Einstein College of Medicine | Low accrual. Study formally terminated by PI on 12/1/2017 | Enrollment / accrual |
| NCT00968799 | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A… | N/A | terminated | Aug 31, 2009 | Cantonal Hospital of St. Gallen | poor patient accrual | Enrollment / accrual |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent… | Phase 2 | withdrawn | Feb 21, 2023 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Program changed | Other (stated, no rule matched) |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | May 1, 2019 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based… | Phase 1 / Phase 2 | terminated | Apr 20, 2021 | Xennials Therapeutics Australia Pty Ltd | Study was terminated by IP Holder (collaborator), PinotBio Inc. | Other (stated, no rule matched) |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With… | Phase 2 | terminated | Nov 30, 2016 | Marker Therapeutics, Inc. | Futility analysis did not support continuation of the trial | Efficacy / futility |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | — | withdrawn | Sep 30, 2021 | Indiana University | PI decision to cancel research | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23,… | Phase 1 | terminated | Sep 24, 2020 | Shanghai East Hospital | Both the sponsors and collaborator are considering terminating the study. | Other (stated, no rule matched) |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing… | Early Phase 1 | terminated | Dec 26, 2017 | National Cancer Institute (NCI) | it was decided that due to lack of accrual on the trial, and low potential for accruing over the… | Enrollment / accrual |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian,…(ORION-01) | Phase 1 / Phase 2 | terminated | Apr 4, 2017 | National Cancer Centre, Singapore | The study had poor efficacy. | Efficacy / futility |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian… | Phase 2 | terminated | Sep 14, 2016 | Translational Research in Oncology | not stated | Not stated |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | Phase 2 / Phase 3 | withdrawn | Mar 12, 2021 | Menoufia University | Poor accrual | Enrollment / accrual |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian… | Phase 3 | terminated | Oct 1, 2018 | AGO Research GmbH | Insufficient Recruitment | Enrollment / accrual |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | Phase 2 | terminated | Nov 23, 2009 | Morphotek | Study was terminated by sponsor due to futile results in NCT00849667 study. | Other (stated, no rule matched) |
| NCT03945786 | Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma | — | suspended | May 10, 2019 | Xuanwu Hospital, Beijing | Recuriting inclusion and exclusion criteria will be changed as COVID-19. | COVID-19 / pandemic |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial… | Phase 1 | withdrawn | Jul 31, 2018 | Washington University School of Medicine | Trial may move forward as an NCI-sponsored trial and not an investigator initiated trial. | Investigator |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian… | Phase 1 | terminated | Aug 1, 2018 | MaxCyte, Inc. | Sponsor shift in focus | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | Phase 2 | terminated | Jan 24, 2017 | NanOlogy, LLC | Business reasons | Sponsor / business decision |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological… | N/A | withdrawn | Apr 4, 2019 | Rutgers, The State University of New Jersey | The study was never initiated, no patients were enrolled. It has been closed with the IRB. | Enrollment / accrual |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | Apr 12, 2011 | Steinar Aamdal | The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol with… | Other (stated, no rule matched) |
| NCT00285415 | A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed… | Phase 2 | terminated | Feb 2, 2006 | Carilion Clinic | Investigator abruptly left Carilion. | Investigator |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | Phase 1 | terminated | Oct 27, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT01939028 | Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery | N/A | terminated | Sep 11, 2013 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Phase 1 | terminated | Mar 10, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive…(HIPEC) | Phase 2 | withdrawn | Jul 2, 2015 | Krankenhaus Barmherzige Schwestern Linz | actually limited personnel ressources | Other (stated, no rule matched) |
| NCT04125225 | What Are the Experiences of Patients With Pseudomyxoma Peritonei? | — | withdrawn | Oct 14, 2019 | University of Southampton | No participants enrolled. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 7, 2023source: clinicaltrials